Medical Isotopes

Energy Fuels is advancing efforts to produce medical isotopes from the Company’s existing uranium and rare earth process streams to support innovative and emerging cancer treatments called “Targeted Alpha Therapy” or “TAT.” TAT takes aim directly at cancerous cells while minimizing damage to healthy cells, representing a potential breakthrough in the treatment of this devastating disease. Energy Fuels’ recent acquisition of RadTran is an important step toward creating a supply chain of R&D quantities of Radium-226 and Radium-228 needed in the near-term for further research and clinical trials, and potentially for commercial quantities in the future. At the current time, radium is extremely expensive and difficult to procure.